Shoenfeld Y, Krause I, Kvapil F, Sulkes J, Lev S, von Landenberg P, Font J, Zaech J, Cervera R, Piette J C, Boffa M C, Khamashta M A, Bertolaccini M L, Hughes G R V, Youinou P, Meroni P L, Pengo V, Alves J D, Tincani A, Szegedi G, Lakos G, Sturfelt G, Jönsen A, Koike T, Sanmarco M, Ruffatti A, Ulcova-Gallova Z, Praprotnik S, Rozman B, Lorber M, Vriezman V B, Blank M
Department of Medicine "B", Sheba Medical Center, Tel-Hashomer, Israel.
J Clin Immunol. 2003 Sep;23(5):377-83. doi: 10.1023/a:1025321617304.
Two-hundred ninety five patients with the antiphospholipid syndrome (APS) were studied for the presence of antibodies against six anti-beta2GPI-related peptides Abs. The prevalence of a wide spectrum of clinical and laboratory parameters of APS was evaluated in all patients, and correlated with the presence of each anti-beta2GPI peptide antibody. The rates of the various antipeptides Abs ranged from 18.0 to 63.7%. Altogether, 87.1% of the patients had antibody reactivity against at least one of the six beta2GPI-related peptides. A high degree of simultaneous reactivity against several beta2GPI-peptides was found. Positive and negative correlations were found between several antipeptides Abs and the rates of thrombosis and fetal loss. Our results point to a heterogeneous activity of antiphospholipid Abs in APS patients, directed, often concurrently, against various epitopes of the beta2GPI molecule. Evaluation of APS patients for the presence of specific antipeptides Abs may be of a value in predicting the risk for future thrombotic and obstetrical complication, as well as for specific therapeutic purposes.
对295例抗磷脂综合征（APS）患者进行了针对六种抗β2糖蛋白I相关肽抗体（Abs）的抗体检测。评估了所有患者中APS广泛的临床和实验室参数的患病率，并将其与每种抗β2糖蛋白I肽抗体的存在情况相关联。各种抗肽抗体的发生率在18.0%至63.7%之间。总共87.1%的患者对六种β2糖蛋白I相关肽中的至少一种具有抗体反应性。发现对几种β2糖蛋白I肽同时具有高度反应性。在几种抗肽抗体与血栓形成率和胎儿丢失率之间发现了正相关和负相关。我们的结果表明，APS患者中抗磷脂抗体具有异质性活性，通常同时针对β2糖蛋白I分子的各种表位。评估APS患者中特定抗肽抗体的存在情况可能有助于预测未来血栓形成和产科并发症的风险，以及用于特定的治疗目的。
